Effects of Medicinal Cannabis on CD4 immunity in AIDS

INVESTIGATOR: Rachel Schrier, Ph.D.

STUDY LOCATION: University of California, San Diego

PROJECT TITLE: Effects of Medicinal Cannabis on CD4 immunity in AIDS

PROJECT TYPE: Pre-Clinical Study, Sub-Study



Multiple scientific reviews have concluded that although some research reports immunosuppressive consequences of cannabis, additional research which includes cost/benefit approach and effects of therapeutic doses on specific immune responses is needed to evaluate cannabis as an agent to treat pain, reduce nausea and wasting in patients with severe disease such as AIDS and cancers. Anesthetic reagents are generally immunosuppressive for CD4 T-cell activity, which would impact patients whose immune system is fragile. However, if cannabis allows HIV infected patients to better tolerate anti-retroviral treatment (which increases CD4 number), reverses wasting, and avoid use of opiates, then it could have an overall beneficial effect. My laboratory has been examining lymphoproliferative responses in HIV infected cohorts and has shown association of positive responses to CMV and mycobacterium with resistance to disease caused by these agents.

This is a proposal to examine the effects of cannabis use on CD4 T-cell proliferation and cytokine expression in HIV infected patients. To conserve costs and rather than setting up a separate study, this an added set of evaluations in Dr. Ron Ellis's clinical study to examine the effectiveness of cannabis in treating neuropathic pain in AIDS patients. That proposal is a cross-over study with pre-and post treatment evaluations. This proposal will involve taking peripheral blood samples at each evaluation point and measuring lymphoproliferative and cytokine production (interferon gamma) in response to HIV, CMV, mitogen, Candida, Toxoplasma, and mycobacterium antigens. All of these antigens are currently in use in our lab and elicit responses in 30-95% of patients. The study structure (N=30) will be a single group, double-blind, cross-over trial comprising five phases: (1) one week baseline; (2) one week smoked cannabis-active; (3) two weeks Washout A; (4) one week smoked cannabis-placebo; and (5) two weeks Washout B.




Meeting Abstract Schrier, R., Soto, P., Hamlat, C., Durand, D., Ceci, K., Ellis, R. (2004, 3). Effects of in Vitro Cannabinoids on T-cell Responses of HIV Infected Patients. Poster presented at the 10th Society on Neuroimmune Pharmacology Conference (Santa Fe, NM).

Weed Is Everywhere, So Why Is It Still A Medical Mystery?

Seeker, June 23, 2019

Regulators hungry for evidence as FDA weighs allowing CBD in food, dietary supplements

Angelica LaVito, CNBC, May 31, 2019

Food and Drug Administration regulators grilled manufacturers and advocates Friday for evidence that CBD actually does anything they claim it does.

Companies are adding CBD, short for cannabidiol, to just about everything, including makeup, tea, pet treats and soft drinks — even though there's little data to support the many claims of its benefits. FDA regulators trying to learn more about the cannabis compound held the agency's first hearing on it Friday.

More than 100 people testified at the hearing. Speakers pushed the FDA to set up a regulatory framework to legally add CBD to food products and dietary supplements. They praised CBD and the purported benefits — and FDA panelists repeatedly asked for data. Scientists warned of the little research and many potential risks CBD brings.

Read the story here

Three years into legal cannabis and California still doesn’t have a reliable test for driving while high

Brooke Staggs, Orange County Register, May 31, 2019

Nearly three years after California voters approved a cannabis legalization bill that promised, among other things, to clarify the issue of driving while high, researchers and law enforcement have few concrete answers about a potentially deadly problem.

It’s unclear, for example, if marijuana-related arrests or car crashes have increased statewide. It’s up to each county to track that data, and many still don’t distinguish between cannabis and other drugs in their arrest and accident reports.

There also aren’t yet any reliable methods for testing whether drivers were actually impaired by marijuana when they’re behind the wheel. Research in this area is hampered by federal law and left scrambling to catch up with the wave of marijuana legalization that continues to sweep the country.

Read the rest of the article here

More News

Click here to access the CMCR news archives.

Igor Grant, MD

Marijuana as Medicine: Can We See Past the Smoke?
North American Cannabis Summit presentation January 2019 (PDF)

Igor Grant, MD

CMCR Symposium, June 2018

Daniele Piomelli, MD, PhD, PharmD

The health impact of cannabis
CMCR Symposium, June 2018

Ziva Cooper, PhD

Therapeutic potential of cannabis for pain alone and as an adjunct to opioids
CMCR Symposium, June 2018

Iain McGregor, PhD

Medicinal cannabis research down under: Introducing the Lambert Initiative for Cannabinoid Therapeutics
CMCR Symposium, June 2018

Copyright © 2019 CENTER FOR MEDICINAL CANNABIS RESEARCH. | University of California, San Diego
cmcr@ucsd.edu | HNRP |